These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
5. [10 years of interferon treatment in multiple sclerosis. Does the future belong to high-dose therapy?]. MMW Fortschr Med; 2003 May; 145 Suppl 2():108. PubMed ID: 14579501 [No Abstract] [Full Text] [Related]
6. Are magnetic resonance findings predictive of clinical outcome in therapeutic trials in multiple sclerosis? The dilemma of interferon-beta. McDonald WI; Miller DH; Thompson AJ Ann Neurol; 1994 Jul; 36(1):14-8. PubMed ID: 8024255 [No Abstract] [Full Text] [Related]
7. [Interferon-beta treatment of progressive disseminated sclerosis. Is it possibly without effect?]. Foldspang A Ugeskr Laeger; 1999 Aug; 161(31):4418-21. PubMed ID: 10487112 [No Abstract] [Full Text] [Related]
8. Key issues in the diagnosis and treatment of multiple sclerosis. An overview. O'Connor P; Neurology; 2002 Sep; 59(6 Suppl 3):S1-33. PubMed ID: 12448786 [No Abstract] [Full Text] [Related]
9. Interferon beta-1a and beta-1b for treatment of multiple sclerosis. Kappos L Lancet; 2002 Nov; 360(9343):1428; author reply 1428-9. PubMed ID: 12424020 [No Abstract] [Full Text] [Related]
11. Are clinical trials of therapeutic agents for MS long enough? Rudge P Lancet; 1999 Mar; 353(9158):1033-4. PubMed ID: 10199348 [No Abstract] [Full Text] [Related]
12. Ethical considerations raised by the approval of interferon beta-1b for the treatment of multiple sclerosis. Goodkin DE; Kanoti GA Neurology; 1994 Jan; 44(1):166-70. PubMed ID: 8290058 [No Abstract] [Full Text] [Related]
13. Perils and pitfalls in the interpretation of clinical trials: a reflection on the recent experience in multiple sclerosis. Goodin DS Neuroepidemiology; 1999; 18(2):53-63. PubMed ID: 10023128 [TBL] [Abstract][Full Text] [Related]
14. Beta interferons for multiple sclerosis. Med Lett Drugs Ther; 2002 Oct; 44(1141):88-9. PubMed ID: 12381969 [No Abstract] [Full Text] [Related]
15. Neutralising antibodies against interferon beta in multiple sclerosis. Giovannoni G; Deisenhammer F Lancet; 2004 Jan; 363(9403):166-7; author reply 168-9. PubMed ID: 14726177 [No Abstract] [Full Text] [Related]
16. 10 years of interferon beta-1b (Beta feron therapy. Kappos L; Hartung HP J Neurol; 2005 Sep; 252 Suppl 3():iii1-iii2. PubMed ID: 16170493 [No Abstract] [Full Text] [Related]
17. [Interferon beta and copolymer-1: mechanism of action and clinical effects in multiple sclerosis]. Losy J Neurol Neurochir Pol; 2000; 34(3 Suppl):63-9. PubMed ID: 10983302 [TBL] [Abstract][Full Text] [Related]
18. Alemtuzumab versus interferon beta-1a: implications for pathology and trial design. McFarland HF Lancet Neurol; 2009 Jan; 8(1):26-8. PubMed ID: 19081510 [No Abstract] [Full Text] [Related]
19. Needed in MS: evidence, not EVIDENCE. Kieburtz K; McDermott M Neurology; 2002 Nov; 59(10):1482-3. PubMed ID: 12451186 [No Abstract] [Full Text] [Related]